#USA #San Diego #Lundbeck #bexicaserin #AAN2025

Lundbeck Showcases Positive Bexicaserin Pipeline Data at AAN Annual Meeting 2025

Lundbeck, the prominent biopharmaceutical company, is gearing up to present its substantial data on bexicaserin at the 2025 Annual Meeting of the American Academy of Neurology (AAN) in San Diego, California. This presentation will include notable interim results from the open-label extension of the PACIFIC trial, which is focused on developing bexicaserin as a remedy for seizures stemming from Developmental and Epileptic Encephalopathies (DEEs).

Understanding Developmental and Epileptic Encephalopathies (DEEs)

Developmental and Epileptic Encephalopathies represent a serious category of epilepsies characterized by drug-resistant seizures, as well as developmental complications that can lead to regression. Research indicates that DEEs are linked to a range of genetic and acquired causes, involving over 900 implicated genes. Despite the serious implications for those affected, approved therapies are scarce, leaving a significant gap in treatment options.

Bexicaserin: An Innovative Approach

Bexicaserin, under investigation by Lundbeck, is an oral treatment designed to target the 5-HT2C receptor, aiming to mitigate seizures in patients diagnosed with DEEs. The open-label extension study involved participants who had successfully completed the initial PACIFIC trial, aiming to assess the drug’s long-term safety and efficacy over a period of up to 52 weeks.

Recent findings from the interim analysis of this ongoing trial have revealed a consistently favorable safety profile for bexicaserin. Most notably, it indicated a 57.3% reduction in countable motor seizures and an impressive 61.2% decrease in total seizures among participants newly transitioned from placebo to bexicaserin. In fact, over 50% of these new participants experienced a significant reduction of 50% or more in their seizure counts compared to baseline.

Insights from Lundbeck Leadership

Johan Luthman, Executive Vice President and Head of Research and Development at Lundbeck, expressed optimism regarding the potential impact of bexicaserin, noting, "The PACIFIC trial has demonstrated that bexicaserin could serve as a vital treatment option for patients afflicted by various DEEs. Our commitment to addressing the needs of this neuro-rare space continues to grow, and we anticipate fruitful discussions with the neuroscience community during the AAN conference."

Additional Presentations on Eptinezumab

In addition to bexicaserin, the company is set to reveal new analyses pertaining to eptinezumab, focusing on real-world data and various clinical trials aimed at enhancing the quality of life for people living with migraines. These presentations will delve into the effectiveness of eptinezumab in reducing migraine frequency, improving patients’ monthly good days, and sustaining treatment responses.

Details of the Connference Schedule

The presentations will unfold as follows:

• - Bexicaserin Oral Presentation - Scheduled for Monday, April 7, during Session S20, from 4:18 PM to 4:30 PM PT.
• - Eptinezumab Poster Presentations - Covering various aspects of treatment outcomes and patient quality of life improvements.

Final Note on Lundbeck

Lundbeck remains steadfast in its mission to innovate and deliver transformative medications, particularly in the realm of brain health, which addresses complex neurological challenges often with limited treatment options. Their ongoing research reflects a deep commitment to enhancing patient care and tackling the stigma surrounding neurological disorders. For more information about their initiatives and progress, one can visit their official website at www.lundbeck.com.

As the AAN Annual Meeting approaches, the neuroscience community watches closely as Lundbeck seeks to share its latest insights and advances, with the aim of improving and enriching the lives of patients and families affected by epilepsy and other neurological disorders.